GlassScriptPhysician profile
Wiley D Truss
NPI 1619267861
$4,808.98
in general payments reported to CMS, 2019-2025
31 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.76 · 2020: $85.25 · 2021: $213 · 2022: $851 · 2023: $1,183 · 2024: $1,058 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,290.14 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $963.38 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $515.40 | 2020-2025 | Entyvio |
| Abbvie INC. | $369.55 | 2022-2025 | Rinvoq, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $243.62 | 2021-2024 | Dificid |
| Genzyme Corporation | $210.13 | 2022-2025 | |
| Ardelyx, INC. | $186.06 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $135.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $123.62 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $111.72 | 2021-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $78.20 | 2022-2024 | Linzess |
| Evoke Pharma, INC. | $69.65 | 2023-2024 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $69.41 | 2022-2025 | Dupixent |
| Pfizer INC. | $57.95 | 2025 | |
| Phathom Pharmaceuticals, INC. | $47.39 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.81 | 2025 | Iqirvo |
| Organon LLC | $44.10 | 2023-2024 | Hadlima, Renflexis |
| Lilly USA, LLC | $37.00 | 2025 | Omvoh |
| Ucb, INC. | $21.37 | 2020 | |
| Celltrion USA INC. | $21.06 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $18.28 | 2022 | |
| Exact Sciences Corporation | $18.23 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $17.54 | 2023 | |
| Novo Nordisk INC | $16.58 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $15.94 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.80 | 2022 | |
| Capsovision, INC. | $15.33 | 2023 | Capsocam Plus |
| Micro-Tech Endoscopy USA, INC. | $14.44 | 2021 | |
| Amgen INC. | $14.31 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.53 | 2022 | |
| Ambu INC. | $8.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wiley Truss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.